Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04369664 · ClinicalTrials.gov registry record · Phase 4
CHOlesterol Lowering and Residual Risk in Type 2 Diabetes
A Phase 4 study, sponsored by NYU Langone Health.
- Completed
- Registry status
- Phase 4
- Development phase
- 151
- Enrollment target
NCT04369664 is a Phase 4 study that has completed, run by NYU Langone Health. The registered enrollment target is 151 participants.
The verdict
NCT04369664, a Phase 4 study, has completed, sponsored by NYU Langone Health.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 151 participants
- Enrollment target
Study Summary
The purpose of this study is to investigate why individuals with type 2 diabetes are at increased risk for heart disease and stroke. This study will investigate risk factors for heart disease and stroke, including platelet (involved in clotting) activity, inflammation, blood vessel wall function, and genetic information (blueprints of your cells), in participants with type 2 diabetes and elevated cholesterol. This study will also include a control group - subjects with elevated cholesterol who do not have diabetes. All participants will be given cholesterol-lowering medicines (PCSK9 inhibitor and statin or ezetimibe) for 1 month with the same risk factors being measured following cholesterol reduction. This study will help understand why individuals with type 2 diabetes are at higher risk for heart disease and stroke before and even after cholesterol reduction.
Interventions
- DRUG Statin
- DRUG Ezetimibe 10mg
- DRUG PCSK9 inhibitor
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 151 participants |
| Start Date | 2020-08-12 |
| Est. Completion | 2023-10-19 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04369664
The ClinicalTrials.gov registry entry for NCT04369664 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 151 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is NYU Langone Health, which has 1,164 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Statin is the first listed.
NCT04369664 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04369664 about?
NCT04369664 is a clinical study titled "CHOlesterol Lowering and Residual Risk in Type 2 Diabetes". The purpose of this study is to investigate why individuals with type 2 diabetes are at increased risk for heart disease and stroke. This study will investigate risk factors for heart disease and stroke, including platelet (involved in clotting) activity, inflammation, blood vessel wall function, an...
What is the current status of trial NCT04369664?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 151 participants. The study started on 2020-08-12. Estimated completion is 2023-10-19.
What interventions are being tested in trial NCT04369664?
The interventions under investigation include: Statin (DRUG), Ezetimibe 10mg (DRUG), PCSK9 inhibitor (DRUG).
Who is sponsoring clinical trial NCT04369664?
This trial is sponsored by NYU Langone Health, which has 1,164 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.